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Introduction
Hepatocellular carcinoma (HCC) is the fifth most common 
cancer and the most common primary liver malignancy 
worldwide (1,2). Most cases of HCC in Asia are hepatitis B 
related, which is prevalent in the region (3). It is the third most 
common cancer causing death in Hong Kong (4). However, 
the prognosis of majority of HCC patients remained poor 
due to low resectability rate of 20% (5,6).
Transplant criteria
Liver transplantation (LT) remains the best curative 
surgical treatment option for patients with HCC and 
cirrhosis. It removes the tumorous liver as well as corrects 
the underlying disease liver, and a 5-year post-transplant 
survival rate of >70% is expected (7-10). The established 
Milan criteria (11) and the UCSF [University of California, 
San Francisco] criteria (12) had been well validated and were 
used as the guideline to list the patients for LT, especially 
deceased donor LT. Unfortunately, its applicability of LT is 
limited by the shortage of liver graft supply (13).
Patients, who suffered from HCC with or without poor 
liver function, who were out of the transplant criteria, 
remained the most difficult group to be treated. Disease 
could be downstaged or controlled by various anticancer 
therapies, which might bring them chance of undergoing 
a curative treatment such as LT. Local ablative therapies, 
chemoembolization and/or targeted therapy were used. 
Some of the tumors showed response to the therapies, 
however the optimal type of therapy that should be used 
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and the upper limit of tumor size that should be downstaged 
were still not clear. A disease-free period of at least three 
months was recommended after the disease was downstaged 
(14-17); unfortunately, the optimal waiting time to offer LT 
remained unclear.
The interval between HCC diagnosis and LT is an 
important prognostic factor, as drop out rate from the 
waiting list as a result of tumor progression increases in a 
time-dependent manner (18). This is particular the case 
because of the scarcity supply of the liver grafts, hence 
patients on the LT waiting list have to suffer from a long 
period of waiting time, result in disease progression and 
drop out from the waiting list (19-21). A predicted 12% 
probability of 6-month drop out for patients in whom the 
tumor is left untreated during the waiting period (19,22).
In view of this, bonus Model for End-Stage Liver 
Disease (MELD) score are granted for patients for stage 
2 HCC (single HCC between 2 and 5 cm or up to three 
HCCs with none larger than 3 cm). Initial MELD score of 
22 points and additional MELD points every 3 months if 
their tumors remained at stage 2 was given in the United 
States. In Hong Kong, patients with HCC that remained at 
stage 2 six months after their tumors had been confirmed 
as stage 2 HCCs by imaging were assigned an arbitrary 
MELD score of 18 points. Two MELD points were added 
every three months. The policy of a 6-month waiting period 
has benefited HCC patients in the deceased donor LT 
waiting list who practically have no chance of undergoing 
living donor LT (23).
Despite the bonus points, the drop out rate was still 
substantial (24). Increase tumor burden during a long 
period of waiting time might also adversely affect post-
LT survival rate (25). Bridging therapy focused on treating 
patients within the criteria while they were on the waiting 
list, in order to avoid tumor progression to more advanced 
stage and therefore drop out from the waiting list. Bridging 
therapy was estimated to decrease drop out rate for HCC 
meeting the Milan criteria to 0–10%. To minimize the 
number of drop out from the waiting list and reduce the 
potential risk of recurrent tumor after LT, intervention 
strategies such as transarterial chemoembolization (TACE) 
and image guided ablative therapies have been offered to 
the patients. Effective bridging therapy during the waiting 
period would help to slow down the disease progression, 
and therefore, allow them to undergo deceased donor LT. 
Tumor recurrence rate after LT was found to increase 
from 12% for patients remaining within Milan criteria, 
either spontaneously or following bridging therapy, to 
45% for those who had a tumor progression beyond the 
Milan criteria (11,26). Therefore, neoadjuvant therapy to 
control tumor growth and vascular invasion of the HCC 
and thereby avoidance of drop out during waiting time is of 
paramount importance. TACE has been used widely and is 
the most common bridging therapy. 
This review focuses on various bridging and downstaging 
modalities in the treatment of HCC, in preparing patients 
for LT.
Diagnostic criteria for hepatocellular carcinoma 
(HCC) and pre-liver transplantation (LT) work up
The diagnostic criteria for HCC in our center were as 
follows: (I) typical abnormality with arterial enhancement 
and contrast washout in the portal venous phase in 3—
phases contrast enhanced computed tomography (CT) or 
magnetic resonance imaging and/or (II) an elevated serum 
Alpha fetoprotein (AFP) level of greater than 400 ng/mL. 
Needle tumor biopsy was generally avoided in resectable 
cases to avoid the risk of needle tract seeding of tumor cells. 
The diagnosis of HCC was confirmed histologically in the 
resected or transplanted specimen. Major vascular invasion 
was defined as tumor thrombosis inside the major branch of 
the portal vein or hepatic vein macroscopically. In our centre, 
dual—tracer positron emission tomography (PET) with [11C] 
acetate and [18F] fludeoxyglucose (FDG) scan, or CT thorax 
and bone scan, were also used as part of the LT work up. 
Dual—tracer PET scan with the additional use of [11C] could 
further improve the sensitivity and specificity in diagnosis 
of HCC and detection of metastasis to 96.8% and 91.7% 
respectively (27). Furthermore, PET scan had been used to 
predict the HCC with poor differentiation as well as presence 
of microvascular invasion especially by the [18F] tracer (28).
 
Liver resection
Liver resection can be used as a form of primary treatment 
for HCC or as a bridging or down staging for LT. Liver 
resection can potentially control tumor growth with clear 
resection margin; in addition, it allows assessment of the 
tumor biology, such as tumor differentiation, presence of 
microvascular invasion, or capsular effraction, and provides 
hints for those patients who should be evaluate for earlier 
LT if possible (29). 
Simple liver resection can only be performed in selected 
patients. Single exophytic or superficial tumor such as 
subcapsular neoplasms, or tumors in the left lobe are better 
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tumors to be performed in bridging or downstaging setting. 
Liver resection can allow salvage LT to be performed as 
the only curative measure if the tumors are still within the 
criteria after a period of wait and see. Reports suggested 
that the post–operative course, complications, and the 
3- and 5-year survival rates did not differ significantly 
between cirrhotic HCC patients undergoing primary LT or 
secondary LT after the initial liver resection (30), especially 
those tumors initially submitted to liver resection with the 
Milan criteria (31,32), or the UCSF criteria (33). In our 
centre, approximately 80% of patients were still eligible for 
salvage LT at the time of tumor recurrence (34). However 
liver resection had risk of surgical complications, and it 
could only be performed in well-compensated patients 
without severe portal hypertension. Poor liver function, 
which was reflected by the high Child-Pugh grading, high 
indocyanine green retention rate at 15 minutes, i.e., >14% 
in major resection and 22% in minor liver resection (35), 
as well as thrombocytopenia were shown to be independent 
predictor of morality in patients with HCC and cirrhosis 
(14,36), and therefore, contraindicated for liver resection. 
Furthermore, the operated abdomen can make the 
subsequent LT technically more difficult and demanding, 
with a higher risk of post-operative complications (37).
Transarterial chemoembolization (TACE)
TACE has been proven to improve survival and control 
symptom (38). It has the advantage of instillation of the 
chemotherapeutic agent directly into the liver tumor, 
which was carried by the lipiodol, as well as ischemic 
necrosis induced by arterial embolization. It has been used 
for unresectable HCC in patients who are awaiting LT 
as well as those who are not transplant candidates opted 
for palliative care (39,40). Adequate tumor necrosis was 
achieved in the explant liver in the range of 27–57% in 
patients within Milan criteria (41,42). The use of TACE did 
not only to affect the features of tumor lesions, but also to 
impact recurrence rate of HCC after LT (41).
Various reports had suggested some of patients could be 
bridged as well as downstaged, which resulted in favorable 
long-term outcome (43-46). Unfortunately, not all patients 
responded to TACE. AFP level >100 ng/mL and high 
3-year calculated survival probability might predict a good 
response to downstaging therapy after TACE (17). The 
aim is to achieve 100% necrosis of the tumors, but less 
than 30% of the cases could achieve complete pathological 
responds in the histological evaluation (41,45,47,48), hence 
the reported necrosis rate in the survival benefit after 
downstaging by TACE remained questionable (41,45,46,49). 
There was also report suggesting partial necrosis was a risk 
factor for tumor recurrence after LT (50). A recent study 
had shown that the significant of to achieve complete or 
nearly complete pathological response as bridging therapy 
improved long term survival after LT as it decreased the 
active tumor load (51). Moreover, a multicenter study 
suggested that preoperative loco-regional therapy decreased 
the risk of tumor recurrence in patients with pathologic 
T2 and T3 HCC (52). In addition, larger degree of tumor 
necrosis, i.e., >60%, of the largest tumor in the explant 
resulted in significant better survival than those with less 
degree of tumor necrosis (15). Afterall, sustained response 
to TACE would be a better selection criterion for LT than 
the initial assessment of tumor size or number (53). Majno 
et al. found a significantly prolonged recurrence-free 
5-year survival of 71% in patients successfully downstaged 
with TACE compared to 29% where TACE did not lead 
to tumor reduction (41). Decaens et al. used TACE as the 
bridging therapy in a mean waiting time of 4.2 months 
which resulted >80% of tumor necrosis in the explants 
without significant difference in the long term survival (46). 
While another study didn’t find significant difference 
in terms of the recurrent rate, however it attributed the 
possibility difference in the pathologic characteristic in which 
TACE group might have larger tumor without presence 
of the capsules (54). TACE given before LT was found 
useful for those patients with tumors >3 cm. Despite the 
controversy, TACE remained one of the commonest bridging 
and downstaging modalities. However it had to be balanced 
with the large tumors that were generally considered poor 
candidates for LT. The low incidence of recurrence for the 
tumor being downstaged within Milan criteria was similar to 
the patients with smaller tumors to start with, and therefore 
should not be excluded from LT (41).
Afterall, TACE is not applicable to every patient with 
cirrhosis. Patients who suffered from ascites and main 
portal vein thrombosis resulted from cirrhosis, poor liver 
function at risk of liver failure, poor renal function at risk of 
contrast nephropathy, difficult arterial anatomy and difficult 
cannulation are contraindication from TACE (38,55). 
These patients are at risk of tumor progression without any 
intervention. Therefore other forms of bridging therapy 
must be attempted and developed. Side effects range from 
post-embolization syndrome, tumor necrosis and rarely 
liver failure. The judicious use of the TACE would certainly 
help as a bridging and downstaging modality to LT.
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Doxorubicin eluting bead (DEB) transarterial 
chemoembolization (TACE) 
DEB aimed to bind, deliver and elute doxorubicin directly 
to the tumorous tissue in a sustained fashion (56-58). There 
are three substantial pharmacokinetic advantages associated 
with DEB: a continuous elution of the drug for prolonged 
period of time, a higher concentration locally into the 
tumor and a lower systematic exposure to the drug in 
comparison to TACE (56).
Despite reports suggested that there was no significant 
difference in terms of the safety profile, tumor response, 
tumor recurrence and overall survival rate for DEB as 
compared to TACE in non-transplant patients (57,59), 
DEB was shown to have lower tumor recurrence rate 
after LT and was identified as an independent predictor of 
recurrence-free survival in the multivariate analysis (60). 
Further study should be carried out to confirm the 
superiority of this technique.
Radiofrequency ablation (RFA)
RFA made use of the radiofrequency (RF) electrode tip, 
generating alternating electrical current (300–1,000 kHz), 
inducing temperature of 60–100 ℃. Irreversible damage 
was resulted by the coagulation necrosis. RF electrode tip 
could generate an ablative zone of 3–5 cm in diameter (61). 
An ablative margin of 0.5–1 cm of the peritumoral tissue 
was necessary as if a clear resection margin achieved during 
the resection of the HCC, and it should be able to be 
visualized by the ultrasound for both open and percutaneous 
procedures. The use of central bile duct cooling during 
RFA of periductal HCC was effective in preventing thermal 
injury of bile duct (62). However, the presence of the ‘heat-
sink effect’ may affect the complete ablation of the tumor 
near the major vessels, and therefore increase the chance of 
local recurrence after RFA (63,64).
The use of RFA was proven to be safe and effective 
treatment modality for patients with advanced cirrhosis 
and non-resectable HCC (65). Majority of the lesions 
were shown to have high tumor necrotic rate (66), and 
especially for those HCC less than 3 cm in size (67-69). 
The drop out rate from the transplant list had decreased 
after treatment with RFA (67,68). Unfortunately, the 
remarkable necrotic effect was less than 50% when used 
in larger tumors (67-69). In fact, tumor size larger than 
3 cm was found to be the risk factors for persistent HCC 
after the treatment (68,69). In addition, the procedure 
may be associated with a higher rate of satellite nodules 
occurrence (66). There are some limitations associated 
with the use of RFA. RFA could not be used in large tumor, 
preferred less than 5 cm (70), and its greatest effect as 
bridging therapy was found in patients with tumors 3 cm or 
smaller who were listed less than 1 year for transplant (71). 
Whereas higher rate of recurrence exceeding the Milan 
criteria was found in patients, especially for patient who 
had a larger tumor size (>2 cm) and/or a higher AFP 
level (>100 ng/mL) at their initial presentation and early 
recurrence after initial RFA (72).
Complications of RFA can be classified into collateral 
thermal damage, direct mechanical injury or other 
uncommon reported complications, such as haemobilia (73), 
liver failure (74), cardiac tamponade (75), liver abscess in the 
presence of bilioenteric anastomosis (76). Tumor seeding 
could be a potential problem, although rare ~0.3–0.5% 
(76,77), especially in the setting of bridging therapy, which 
may render potential LT impossible.
Microwave ablation (MWA)
MWA made use of the electromagnetic energy, creating an 
electromagnetic field that allowed rapid and homogenous 
heating of the tissue and resulted in heat-based thermal 
cytotoxicity from frictional heating from the rapid 
oscillation of water molecules (78). It also converted kinetic 
energy into heat through ionic polarization, therefore 
coagulation necrosis. Similar to RFA, the lesion should 
be able to be visualized by the ultrasound for proper 
localization. It created a predictable and reproducible area 
of tissue necrosis, and it could ablate the tumor capsule 
as well as surrounding extracapsular invasion. For larger 
tumors, multiple needle electrode insertions might be 
needed for complete tumor ablation (79). MVA appeared 
to be less susceptible to heat sink effects than RFA (80), 
which might be more effective near the hepatic veins and 
IVC (81). In general, studies had demonstrated similar 
complete ablation rate with RFA (82-85), data also showed 
similar survival rates after RFA and MVA for curative 
treatment for HCC (82,83,86). While MWA was shown 
to be a safe procedure use as a bridge for LT, it also 
allowed complete tumor necrosis (87). Unfortunately, 
there was higher rate of local tumor recurrence, which 
was attributed to the potential tumor seeding by the use of 
larger application (5 mm in diameter) (88). Complications 
are similar to those RFA, including bile duct stenosis and 
haemorrhage, with a potential risk of tumor seeding due to 
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large probe is used (89).
Irreversible electroporation (IRE)
IRE was a non-thermal ablative therapy that used high-
voltage, low electrical current to irreversibly increase the 
permeability of target cells, disrupt cellular homeostasis, 
and induce apoptosis (90). It also induced complete cell 
death up to the margin of large vessels bypassing the heat 
sink effect seen such as in the RFA (91). Up-to-date, there is 
not much data regarding the use of IRE as bridging therapy, 
however complete necrosis was achieved in treatment of the 
tumor <3 cm by IRE (92). There is a potential role of using 
IRE in management patients waiting for LT.
Transarterial radioembolization (TARE)
Radioembolization involved the transarterial infusion of 
microspheres containing Y90 loaded microspheres, iodine-
131-iodized poppy seed oil, or similar agents into the 
hepatic artery by transarterial techniques (93). The highly 
concentrated radioactive substance would be administrated 
to the tumor, while keeping the level of toxicity affecting the 
functional liver parenchyma at the minimal and preserving 
the blood supply (94,95). It was also safe for use in patients 
with portal vein thrombosis (96).
Candidates with good functional status and relatively 
adequate liver reserve with relatively normal liver function, 
low tumor burden without extrahepatic metastasis would 
be the ideal candidate for radioembolization (97). Reports 
found a trend towards shorter times to tumor response 
and longer times to tumor progression were apparent with 
TARE when compared with TACE (98,99), suggesting a 
potential advantage as a bridging therapy in patients waiting 
for LT.
Results of transarterial radioembolization (TARE) 
There are limited papers describing downstaging of HCC 
by means of TARE (96,98,100,101). Downstaging of 
the tumor had been observed in the rate of around 37% 
without significant difference as compare to TACE, while 
the recurrence rate is 26% (102).
However, not all patients could undergo TARE. 
Pre- t rea tment  mesenter i c  ang iogram and  99Tc 
macroaggregated albumin scans were required to assess 
the anatomy and the presence of vascular shunting. This 
helped to minimize the risk of radiation pneumonitis due 
to the shunting. (98,99,103)In case of vascular shunting 
more than >20%, it could be embolized before therapy 
began. It appeared to be a safe treatment modality. The 
side effect is usually mild and limited to fatigue and 
constitutional symptoms (104,105). Nonetheless significant 
side effects due to non-targeted radiation resulted in 
cholecystitis, gastrointestinal ulcers, and pneumonitis were 
reported (43,97,103,106-109).
High intensity focused ultrasound (HIFU)
HIFU was an extracorporeal ablative modality making 
use of multiple ultrasound (USG) beams. It induced heat 
generation, produced mechanical effect and radiation forces, 
aiming at a temperature of 60 ℃ or higher, in order to cause 
coagulation necrosis and cell death. It allowed minimal 
thermal damage to tissue located between the transducer 
and the focal point (110). Clinical results for HIFU ablation 
of the tumor from China produced some encouraging 
findings in terms of significant tumor shrinkage and 
prolonged survival of patients (111-114).
HIFU had been shown to achieve favorable radiological 
responses for patients suffered from unresectable HCC 
and Child-Pugh C cirrhosis (115,116). Satisfactory tumor 
necrosis was also observed according to histological 
examinations of excised livers in a few transplant recipients 
(116,117).
HIFU had been shown to be an effective ablative 
modality in which similar tumor necrosis was achieved 
in in the explant liver as compared to the TACE. It 
had the advantage to be offered to the patients who are 
contraindicated for TACE, i.e., ascites, Child-Pugh C 
cirrhosis, portal vein thrombosis. It had also proven to 
improve the percentage of patients receiving bridging 
therapy in the transplant waiting list (118). In addition the 
number of drop out rate decreased (119). Nonetheless, 
whether this converted any survival benefit after the LT 
remained an area for further research.
Unfortunately, not every HCC could be treated 
by HIFU. It had to be visualized and localized by the 
ultrasound before HIFU could be carried out. It was a safe 
and totally extracorporeal procedure with minimal risk. 
Minor complications such as skin and subcutaneous tissue 
injuries occurred in most patients (116), however, more 
severe complications were reported such as bile duct injury. 
The patient should be fit to undergo general anesthesia, so 
to allow momentarily holding of breathing for more precise 
ablation.
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Stereotactic body radiotherapy (SBRT)
SBRT involved the precision delivery of a highly focused 
dose of radiation to the target tumor over a short number of 
treatments. With the advancement of the imaging methods 
for localizing HCC, precise treatment planning facilitated 
the delivery of targeted radiation with minimal treatment 
of uninvolved tissue (120). Lesions near the bowels were 
not ideal for SBRT since there was risk of gastrointestinal 
perforation and bleeding, however it had the advantage to 
treat the lesions adjacent to the central biliary system that 
were not amenable to surgery or ablation (121).
SBRT had been used as one of the bridging therapies and 
it was found to be effective, safe with low toxicity profile 
(122-124). The dosage given ranged from 40 to 51 Gy. 
Complete necrosis in some of the lesions could be achieved 
at around 27%. Most of the tumors could be decreased in 
size or remained stable without dropped off (123).
Radiation induced liver toxicity
Radiation induced liver disease (RILD) had been defined as 
a clinical syndrome of anicteric hepatomegaly, ascites, and 
elevated liver enzymes occurring from 2 weeks to 4 months 
after radiotherapy. The probability of RILD rose up to 50% 
for a mean dose of 43 Gy given (125). In some severe cases, 
RILD might result in liver failure and mortality. Hence, 
careful administration of the radiation and precise planning 
of the radiotherapy would minimize the complications.
Sorafenib
Sorafenib was an oral multi-kinase inhibitor, which had 
been shown to have significant efficacy in prolonging the 
time-to-progression and was the standard treatment for 
patients with advanced HCC (126,127). Study on the use of 
sorafenib as bridging or downstaging therapy before LT was 
limited. A study on this issue, however, was given in patient 
median times to LT shorter than six months, suggested 
its cost-effectiveness while comparing to those without 
any therapy for T2-HCC patients waiting for LT (128). 
Combination of TACE and sorafenib might be a potential 
therapeutic approach for both bridging and downstaging 
HCC before LT. TACE allowed embolization of the tumor 
feeding vessel with focal chemotherapeutic effect, whereas 
sorafenib inhibited angiogenesis and retarded the tumor 
progression. There were clinical trials and studies working 
on the combination of the sorafenib with other modalities 
before LT (129).
Combination of modalities
Bridging loco-regional therapies should be sued whenever 
possible to prevent drop out and to minimize HCC 
recurrence after LT, particularly when the expected time 
to LT is longer than six months. TACE had been mostly 
studied as both bridging and downstaging protocols, 
especially for multifocal tumors (130). Combinations 
of various loco-regional modalities seemed to be more 
effectively downstage the patients than TACE alone 
(15,131). Given the effects of various modalities, tumor 
necrotic rate would potentially be increased, however 
whether this would convert to survival benefit would 
require confirmation from further studies. The role of the 
combinations of therapies in the bridging or downstaging 
setting is still to be determined.
Conclusions
Different modalities had been use as bridging therapies for 
LT so to decrease the number of drop out rate. At the same 
time, effective downstaging therapies allowed more patients 
to be put into transplant waiting list as long as the diseases 
are remained stable and within the criteria. Combine 
different modalities could be effective in achieve these goals. 
However, identification of tumors that would respond to 
the therapies, and therefore allowed better selection of the 
patients to be transplanted would benefit a more long term 
outcome.
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